Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Headlines

Posted By Global Banking and Finance Review

Posted on January 30, 2025

Former exec at drugmaker Ipsen sentenced to prison for insider trading

By Nate Raymond

BOSTON (Reuters) - A former executive at French drugmaker Ipsen was sentenced on Thursday to two months in prison for illegally trading on inside information he learned about his company's plans to acquire cancer drug developer Epizyme in 2022.

Dishant Gupta, Ipsen's former director of data strategy and operations, was sentenced by U.S. District Judge Julia Kobick in Boston after pleading guilty in October to engaging in securities fraud in order to earn more than $260,000 through insider trading.

Prosecutors had asked the judge to sentence Gupta to one year in prison, while defense lawyers had pushed for a non-custodial sentence. Gupta must also pay a $20,000 fine and forfeit the $260,000, prosecutors said.

His lawyer did not respond to a request for comment.

Prosecutors said that during a meeting in Cambridge, Massachusetts, in March 2022, an Ipsen executive asked Gupta to help him put together materials related to a potential acquisition of a cancer drug and an unidentified drug company's assets.

Days later, Gupta met with Ipsen executives to discuss possible acquisitions in the oncology market, prosecutors said. By April 7, 2022, Gupta knew the cancer drug and assets Ipsen wanted to acquire belonged to Cambridge-based biotech Epizyme, the maker of the cancer medication Tazverik, prosecutors said.

That day, he began buying Epizyme shares in his wife's brokerage account, according to court documents. Prosecutors said he bought more in the days that followed as the companies discussed a potential outright acquisition of Epizyme.

Ipsen announced its $247 million acquisition of Epizyme on June 27, 2022. Gupta then sold all of his Epizyme shares, netting him a profit of more than $262,000, prosecutors said.

"The defendant's crime is a form of corruption," prosecutors wrote in court papers ahead of Thursday's sentencing. "He took advantage of the trust that his employer, and co-workers, placed in him to try and make money."

(Reporting by Nate Raymond in Boston; Editing by Marguerita Choy)

Recommended for you

  • Chief of violence-hit Indian state of Manipur resigns

  • The stark divide that South Africa's land act seeks to bridge

  • 'No thanks', white South Africans turn down Trump's immigration offer